Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 03, 2022
- Source ID
- 10.1111/bjh.18297
Entities
People
- Aleksandar Radujkovic
- Ankit Kansagra
- Bart Scott
- Betul Oran
- Bhagirathbhai R. Dholaria
- Bipin N Savani
- Donal P McLornan
- Ibrahim Yakoub‐agha
- Juan Carlos Hernandez-Boluda
- Mohamed A Kharfan-Dabaja
- Noel Estrada‐merly
- Patrick J. Hayden
- Paul Shaughnessy
- Ryotaro Nakamura
- Soyoung Kim
- Taiga Nishihori
- Tiarlan Sirait
- Tomasz Czerw
- Vincent T. Ho
- Wael Saber
Organizations
- Angiocrine Bioscience (United States)
- Astellas Pharma (United States)
- Biomedical Advanced Research and Development Authority
- Boston Children's Hospital
- Bristol-Myers Squibb
- Chiron Corporation
- City of Hope National Medical Center
- Daiichi Sankyo
- Dana–Farber Cancer Institute
- Fred Hutchinson Cancer Center
- Genzyme
- H. Lee Moffitt Cancer Center & Research Institute
- Health Resources and Services Administration
- Incyte
- Johnson & Johnson
- Kiadis Pharma (Netherlands)
- Kirin Company
- MSD (United Kingdom)
- Mayo Clinic
- Medical College of Wisconsin
- Miltenyi Biotec
- National Cancer Institute
- National Eye Institute
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Marrow Donor Program
- Office of Naval Research
- Omeros Corporation
- Pharmacyclics
- Roche (United States)
- St. Baldrick's Foundation
- Stanford University
- StemCyte
- Trinity College Dublin
- University College Hospital
- University of Texas Southwestern Medical Center
- University of Texas at Austin
- Vanderbilt University
- bluebird bio